These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16125490)

  • 21. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
    Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
    Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus.
    Kuchulakanti PK; Chu WW; Torguson R; Clavijo L; Wolfram R; Mishra S; Xue Z; Gevorkian N; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
    Am J Cardiol; 2006 Jul; 98(2):187-92. PubMed ID: 16828590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
    Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
    J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
    Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
    Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
    Moussa I; Leon MB; Baim DS; O'Neill WW; Popma JJ; Buchbinder M; Midwall J; Simonton CA; Keim E; Wang P; Kuntz RE; Moses JW
    Circulation; 2004 May; 109(19):2273-8. PubMed ID: 15123524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
    Gurm HS; Rajagopal V; Fathi R; Vivekanathan D; Yadav JS; Bhatt DL; Ellis SG; Lincoff AM; Topol EJ
    Am J Cardiol; 2005 Mar; 95(6):716-21. PubMed ID: 15757596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
    JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
    Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic implications of bivalirudin in the cardiac catheterization laboratory.
    Bakhai A; Cohen DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 3():S35-42. PubMed ID: 17224883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
    Borg S; Persson U; Allikmets K; Ericsson K
    Clin Ther; 2006 Nov; 28(11):1947-59. PubMed ID: 17213015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty.
    Cheneau E; Rha SW; Kuchulakanti PK; Stabile E; Kinnaird T; Torguson R; Pichard AD; Satler LF; Kent KM; Waksman R
    Catheter Cardiovasc Interv; 2005 Aug; 65(4):469-72. PubMed ID: 15988741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
    Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results and follow-up after implantation of four or more sirolimus-eluting stents in the same patient.
    Iakovou I; Sangiorgi GM; Stankovic G; Corvaja N; Vitrella G; Ferraro M; Colombo A
    Catheter Cardiovasc Interv; 2005 Apr; 64(4):436-9; discussion 440-1. PubMed ID: 15789401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry).
    Lee MS; Hu PP; Aragon J; Shah AP; Oyama J; Dhoot J; Iqbal Z; Jones N; Penny W; Tobis J; Mahmud E; French W
    Am J Cardiol; 2010 Aug; 106(3):337-41. PubMed ID: 20643242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).
    Nikolsky E; Kosinski E; Mishkel GJ; Kimmelstiel C; McGarry TF; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW
    Am J Cardiol; 2005 Mar; 95(6):709-15. PubMed ID: 15757595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of bivalirudin to prevent subacute thrombosis during drug-eluting stent implantation.
    Medina RP; Foto D
    J Invasive Cardiol; 2004 May; 16(5):236-9. PubMed ID: 15152125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.